XML 48 R38.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands |  |  | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | ---
Jul. 05, 2016 | Sep. 30, 2015 | Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2016
Financial assets and liabilities subject to fair value measurements |  |  |  |  |  |  |
Transfer of assets from Level 1 to Level 2 |  |  | $ 0 |  | $ 0 |  |
Transfer of assets from Level 2 to Level 1 |  |  | 0 |  | 0 |  |
Assets: |  |  |  |  |  |  |
Fair value of assets |  |  | 191,758 |  | 191,758 |  | $ 144,754
Liabilities: |  |  |  |  |  |  |
Contingent consideration payable |  |  | 265,350 |  | 265,350 |  | 269,722
Derivative liability |  |  |  |  |  |  | 265
Deferred compensation plan liability |  |  | 1,994 |  | 1,994 |  | 1,479
Fair value of liabilities |  |  | 267,344 |  | 267,344 |  | 271,466
Contingent consideration payable |  |  | 265,350 |  | 265,350 |  | 269,722
Contingent consideration payable |  |  |  |  |  |  |
Balance, beginning of the period |  |  | 274,300 | $ 277,229 | 269,722 | $ 274,077 |
Payment of contingent consideration in cash |  |  | (10,000) | (5,000) | (10,000) | (5,000) |
Payment of contingent consideration in stock |  |  |  | (6,115) |  | (6,115) |
Unrealized change in fair value change during the period, included in Statement of Operations |  |  | 1,050 | 10,186 | 5,628 | 13,338 |
Balance, end of the period |  |  | 265,350 | $ 276,300 | 265,350 | $ 276,300 |
Other current liabilities |  |  |  |  |  |  |
Foreign Currency Exchange Rate Exposure |  |  |  |  |  |  |
Derivative liabilities |  |  | 0 |  | 0 |  | 300
Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Contingent consideration payable |  | $ 259,000 | 254,700 |  | 254,700 |  |
Contingent consideration payable |  | $ 259,000 | 254,700 |  | 254,700 |  |
MiaMed Inc |  |  |  |  |  |  |
Contingent consideration payable |  |  |  |  |  |  |
Asset acquisition, potential aggregate deal value | $ 89,500 |  |  |  |  |  |
Clinical and Regulatory Approval milestones | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Contingent consideration payable |  |  | 228,100 |  | 228,100 |  |
Contingent consideration payable |  |  | 228,100 |  | 228,100 |  |
Revenue-based milestones | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Contingent consideration payable |  |  | 26,600 |  | 26,600 |  |
Contingent consideration payable |  |  | 26,600 |  | 26,600 |  |
Minimum | Clinical and Regulatory Approval milestones | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Discount rate (as a percent) |  | 0.40% |  |  |  |  |
Minimum | Revenue-based milestones | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Discount rate (as a percent) |  | 1.00% |  |  |  |  |
Maximum | Clinical and Regulatory Approval milestones | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Discount rate (as a percent) |  | 1.10% |  |  |  |  |
Maximum | Clinical and Regulatory Approval milestones | MiaMed Inc |  |  |  |  |  |  |
Contingent consideration payable |  |  |  |  |  |  |
Contingent consideration payable upon achievement of milestones | 83,000 |  |  |  |  |  |
Maximum | Revenue-based milestones | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Discount rate (as a percent) |  | 2.20% |  |  |  |  |
Maximum | Clinical, Regulatory and Commercial milestones | MiaMed Inc |  |  |  |  |  |  |
Contingent consideration payable |  |  |  |  |  |  |
Contingent consideration payable upon achievement of milestones | $ 83,000 |  |  |  |  |  |
ATB200 Pompe program | Clinical and Regulatory Approval milestones | Callidus |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Contingent consideration payable |  |  | 10,300 |  | 10,300 |  |
Contingent consideration payable |  |  | 10,300 |  | 10,300 |  |
Commercial paper |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |
Fair value of assets |  |  | 80,789 |  | 80,789 |  | 68,390
Corporate debt securities |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |
Fair value of assets |  |  | 108,649 |  | 108,649 |  | 74,535
Money market |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |
Fair value of assets |  |  | 2,320 |  | 2,320 |  | 1,829
Level 2 |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |
Fair value of assets |  |  | 191,758 |  | 191,758 |  | 144,754
Liabilities: |  |  |  |  |  |  |
Derivative liability |  |  |  |  |  |  | 265
Deferred compensation plan liability |  |  | 1,994 |  | 1,994 |  | 1,479
Fair value of liabilities |  |  | 1,994 |  | 1,994 |  | 1,744
Level 2 | Commercial paper |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |
Fair value of assets |  |  | 80,789 |  | 80,789 |  | 68,390
Level 2 | Corporate debt securities |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |
Fair value of assets |  |  | 108,649 |  | 108,649 |  | 74,535
Level 2 | Money market |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |
Fair value of assets |  |  | 2,320 |  | 2,320 |  | 1,829
Level 3 |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Contingent consideration payable |  |  | 265,350 |  | 265,350 |  | 269,722
Fair value of liabilities |  |  | 265,350 |  | 265,350 |  | 269,722
Contingent consideration payable |  |  | $ 265,350 |  | $ 265,350 |  | $ 269,722
Level 3 | Revenue-based milestones | Monte Carlo | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Probability of achievement of milestones (as a percent) |  |  |  |  | 66.50% |  |
Revenue volatility (as a percent) |  |  |  |  | 51.00% |  |
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  |  | 1.00% |  |
Probability of achievement of milestones (as a percent) |  |  |  |  | 66.50% |  |
Level 3 | Minimum | Revenue-based milestones | Monte Carlo | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  |  | 1.50% |  |
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  |  | 1.30% |  |
Probability of achievement of milestones (as a percent) |  |  |  |  | 70.00% |  |
Level 3 | Maximum | Revenue-based milestones | Monte Carlo | Scioderm |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  |  | 2.40% |  |
Level 3 | ATB200 Pompe program | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Discount rate (as a percent) |  |  |  |  | 12.50% |  |
Level 3 | ATB200 Pompe program | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Probability of achievement of milestones (as a percent) |  |  |  |  | 32.00% |  |
Level 3 | ATB200 Pompe program | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |
Probability of achievement of milestones (as a percent) |  |  |  |  | 45.00% |  |

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contingent consideration payable in a business asset acquisition upon achievement of certain clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | fold_BusinessAssetAcquisitionContingentConsiderationMilestones
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent consideration payable roll forward. + References No definition available. + Details
Name: | fold_BusinessCombinationContingentConsiderationLiabilityRollForward
Namespace Prefix: | fold_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of assumed revenue volatility, used as an input to measure fair value. + References No definition available. + Details
Name: | fold_FairValueAssumptionsRevenueVolatilityRate
Namespace Prefix: | fold_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of likelihood that milestones will be achieved, used as an input to measure fair value. + References No definition available. + Details
Name: | fold_FairValueInputsProbabilityOfAchievementOfMilestones
Namespace Prefix: | fold_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the payment of contingent consideration liabilities. + References No definition available. + Details
Name: | fold_PaymentOfContingentConsideration
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements. + References No definition available. + Details
Name: | us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 20 -Section 50 -Paragraph 4D -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=64830801&loc=SL51823488-111719 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226000-175313 + Details
Name: | us-gaap_DerivativeFairValueOfDerivativeLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13495-108611 + Details
Name: | us-gaap_DerivativeLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsDiscountRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=fold_MonteCarloMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |